Drugs / Erythrocyte Encapsulated Thymidine Phosphorylase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03866954 | Nov 2024 → Sep 2027 | inborn errors of metabolism, mitochondrial disease | St George's, University of London | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erythrocyte Encapsulated Thymidine Phosphorylase | “Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP)” NCT03866954 ↗ |
| Known as | EE-TP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03866954 ↗ |
| Action | Restore | “replacing functional thymidine phosphorylase” NCT03866954 ↗ |
| Modality | Protein / enzyme biologic | “The potential treatment for MNGIE offered in this trial is an enzyme replacement therapy” NCT03866954 ↗ |
| Route | Intravenous | “All patients will be administered EE-TP by intravenous (IV) infusion.” NCT03866954 ↗ |